Psoriatic patients with a history of cancer: A real-life experience with Apremilast treatment for 104 weeks.
Apremilast
oncological disease
psoriasis
psoriatic arthritis
treatment
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
revised:
10
12
2021
received:
15
07
2021
accepted:
28
12
2021
pubmed:
1
2
2022
medline:
5
10
2022
entrez:
31
1
2022
Statut:
ppublish
Résumé
Psoriasis is a multifactorial, chronic, auto- inflammatory disease, with a worldwide prevalence of around 2%, subtended by robust genetic predisposition and autoimmune pathogenic traits. The disease, mainly involving the skin and joints, is featured by erythemato-squamous lesions, with a chronic relapsing course and relevant systemic comorbidities. Apremilast is a novel oral agent that has recently been made available to dermatologists for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis. Although it is considered as relatively safe molecule with few contraindications, experience with Apremilast in the real-world setting for cancer patients with moderate-to-severe plaque psoriasis is lacking. Hence, we report the real-life experience in patients with psoriasis and a history of cancer who underwent treatment with Apremilast for 104 weeks.
Substances chimiques
Anti-Inflammatory Agents, Non-Steroidal
0
Thalidomide
4Z8R6ORS6L
apremilast
UP7QBP99PN
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15306Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Bernardini N, Skroza N, Tolino E, Mambrin A, Balduzzi V, Marchesiello A, Michelini S, Volpe S, Maddalena P, Proietti I, Potenza C. Recurrent erythrodermic psoriasis and polycythemia successfully treated with brodalumab. Dermatol Ther 2020 Nov;33(6): e14338. doi: 10.1111/dth.14338. Epub 2020 Oct 8. PMID: 32975343
pubmed: 32975343
Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Investig Dermatol. 2013;133:377-385. doi:10.1038/jid.2012.339
Gerdes S, Mrowietz U, Boehncke WH. Komorbidität bei Psoriasis vulgaris. Hautarzt. 2016;67:438-444. doi:10.1007/s00105-016-3805-3
Phan C, Beneton N, Delaunay J, et al. Real-world effectiveness and safety of apremilast in older patients with psoriasis. Drugs Aging. 2020;37(9):657-663. doi:10.1007/s40266-020-00781-y
Yorulmaz A, Hayran Y, Akpinar U, Yalcin B. Systemic immune-inflammation index (SII) predicts increased severity in psoriasis and psoriatic arthritis. Curr Health Sci J. 2020;46(4):352-357. doi:10.12865/CHSJ.46.04.05
Valenti M, Pavia G, Gargiulo L, et al. Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: long-term safety in a single- center real-life population. J Dermatolog Treat. 2021;15:1-5. doi:10.1080/09546634.2021.1886231
Balato A, Campione E, Cirillo T, et al. Long-term efficacy and safety of apremilast in psoriatic arthritis: focus on skin manifestations and special populations. Dermatol Ther. 2020;33(3):e13440. doi:10.1111/dth.13440
Ranganath VK, Yoon J, Khanna D, et al. Western consortium of practicing rheumatologists. Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohort. Ann Rheum Dis. 2007;66(12):1633-1640. doi:10.1136/ard.2006.065839
Helliwell PS, Kavanaugh A. Comparison of composite measures of disease activity in psoriatic arthritis using data from an interventional study with golimumab. Arthritis Care Res. 2014;66(5):749-756. doi:10.1002/acr.22204
Apalla Z, Psarakis E, Lallas A, Koukouthaki A, Fassas A, Smaragdi M. Psoriasis in patients with active lung cancer: is Apremilast a safe option? Dermatol Pract Concept 2019 31;9(4):300-301. doi: 10.5826/dpc.0904a11
Di Lernia V, Casanova DM, Ricci C. Apremilast in patients with history of malignancy: a real-life, single-center experience. Int J Dermatol. 2021;60(1):e22-e24. doi:10.1111/ijd.15093
Challenges in the treatment of psoriasis with biologics: vaccination, history of malignancy, human immunodeficiency virus (HIV) infection, and pediatric psoriasis Kerasia-Maria Plachouri MD, PhD Sophia Georgiou MD, PhD First published: 19 March 2019
Bellinato F, Gisondi P, Maurelli M, Girolomoni G. IL-17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: a case series with systematic literature review. Dermatol Ther. 2021;17:e14889. doi:10.1111/dth.14889
Langley A, Beecker J. Management of common side effects of apremilast. J Cutan Med Surg. 2018;22(4):415-421. doi:10.1177/1203475417748886
Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173(6):1387-1399.
Rapoport BL. Management of the cancer patient with infection and neutropenia. Semin Oncol. 2011 Jun;38(3):424-430. doi:10.1053/j.seminoncol.2011.03.013
Crowley J, Thaçi D, Joly P, et al. Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol. 2017;77(2):310-317.e1. doi:10.1016/j.jaad.2017.01.052
Odorici G, Lasagni C, Bigi L, Pellacani G, Conti A. A real-life experience of psoriatic patients with history of cancer treated with biological drugs. J Eur Acad Dermatol Venereol. 2019;33(12):e453-e455. doi:10.1111/jdv.15775
Dattola A, Del Duca E, Saraceno R, Gramiccia T, Bianchi L. Safety evaluation of apremilast for the treatment of psoriasis. Expert Opin Drug Saf. 2017;16(3):381-385. doi:10.1080/14740338.2017.1288714